Fig. 4
Effect of 3-h incubation with AA and LA on non-SRCC cells (GPM-1), patient-derived gastric origin SRCC (GPM-2), gastric-origin SRCCs (HSC-39 and KATO-3) and human pancreatic (MIA PaCa-2) and ovarian (SKOV-3) lines. A Inhibition curves after: 3-h AA, 3-h AA + 3-h medium + 3-h LA (denoted as AA+LA) or 3-h LA + 3-h medium + 3-h AA (denoted as LA + AA). B IC50 of all cells after 3-h treatments of AA, AA+LA or LA + AA. Minimum threshold of inhibition percentage after: 3-h AA, 3-h AA+LA or 3-h LA + AA in C SRCC and D non-SRCC (n = 3). Significance is reported for the difference (* p < 0.05, ** p < 0.01) between labeled groups and single treatment (e.g., AA). The values are summarized from inhibition percentage of the lowest three concentrations (e.g., AA = 0.206, 0.617 and 1.852 mM) used among treatments (e.g., AA, AA+LA and LA + AA). All data were analyzed by a two-way ANOVA. E Viability of cells after incubations with three different treatments. After treatments, cells were stained with calcein and scanned on a Celigo imaging cytometer